PMID: 12769686May 29, 2003Paper

The MYC oncogene as a cancer drug target

Current Cancer Drug Targets
H Hermeking

Abstract

The universal deregulation of c-myc gene expression in tumor cells suggests that this oncogene represents an attractive target for cancer therapeutic purposes. The same applies to the N-myc gene, which has a more restricted tissue specificity. Translocation (e.g., c-myc in Burkitt's lymphoma), or amplification (e.g., N-myc in neuroblastoma) of myc genes has been causally linked to tumor formation. Furthermore, the c-myc promoter integrates diverse mitogenic signalling cascades, which are constitutively activated in tumor cells, and translates them into expression of the c-MYC transcription factor, which promotes cell proliferation by regulating the expression of numerous target genes. Recent experimental data suggest, that even a brief inhibition of c-myc expression may be sufficient to permanently stop tumor growth and induce regression of tumors. Attempts to identify specific inhibitors of c-MYC/MAX dimerization have yielded promising results. In addition, downstream-target genes of c-MYC represent attractive targets for tumor therapy. Tumor cells expressing c-MYC at elevated levels are sensitized to treatment with DNA-damaging drugs. In mice and presumably also in human patients, the successful treatment of c-myc-induced tum...Continue Reading

Citations

Nov 20, 2008·Cancer Immunology, Immunotherapy : CII·Tatiana M Garcia-BatesRichard P Phipps
Nov 25, 2011·Clinical and Experimental Medicine·Nataša Todorović-RakovićDragica Nikolić-Vukosavljević
Jun 16, 2005·Trends in Molecular Medicine·Catherine M Shachaf, Dean W Felsher
Aug 6, 2011·Journal of the American Chemical Society·Alexis Vallée-BélisleKevin W Plaxco
May 13, 2009·Journal of the American Chemical Society·Dalia I HammoudehSteven J Metallo
Oct 29, 2004·Nature Reviews. Cancer·Eugene W Gerner, Frank L Meyskens
Dec 23, 2011·Proceedings of the National Academy of Sciences of the United States of America·Antje MenssenHeiko Hermeking
Apr 4, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·I SciontiMassimo Serra
Apr 12, 2011·Blood·María J BuenoMarcos Malumbres
Apr 28, 2011·BMC Bioinformatics·Zohar Yakhini, Igor Jurisica
Jul 22, 2009·Molecular Neurodegeneration·Luis B Tovar-Y-RomoRicardo Tapia
Jun 15, 2005·American Journal of Pharmacogenomics : Genomics-related Research in Drug Development and Clinical Practice·Zhuo ZhangHui Wang
Apr 1, 2009·Future Medicinal Chemistry·Giovanna Zinzalla, David E Thurston
Apr 2, 2004·Expert Review of Anticancer Therapy·Edward V Prochownik
Aug 25, 2015·Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology·Dipanjan PanGregory M Lanza
Feb 25, 2015·International Journal of Oncology·Lidia CerquettiAntonio Stigliano
Aug 10, 2015·Current Opinion in Genetics & Development·Jian-Feng XiangLing-Ling Chen
Jul 19, 2013·Journal of Neuropathology and Experimental Neurology·Xian Shuang LiuZheng Gang Zhang
Sep 26, 2008·Chemistry & Biodiversity·Daniela GroteKarlheinz Seifert
Jun 27, 2012·Journal of Molecular Recognition : JMR·Marie-Eve BeaulieuPierre Lavigne
Mar 22, 2014·Journal of Internal Medicine·Y LiD W Felsher
Aug 29, 2006·Seminars in Cancer Biology·Constadina Arvanitis, Dean W Felsher
Jul 16, 2013·Molecular and Cellular Endocrinology·Ali ZekriArdeshir Ghavamzadeh
Sep 4, 2014·Asian Pacific Journal of Tropical Biomedicine·Chinnappan Ravinder Singh, Kandasamy Kathiresan
Dec 21, 2014·Journal of Computer-aided Molecular Design·Hyun-Jin Kang, Hyun-Ju Park
Dec 20, 2014·Future Oncology·Lohith S Bachegowda, Stefan K Barta
Dec 18, 2013·Oncogene·A LiL Chai
Nov 28, 2013·Pharmaceuticals·Olivia PerwitasariRalph A Tripp
Jan 23, 2004·Nature Reviews. Cancer·Heiko Hermeking

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.